PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/20.500.11779/1928
Browse
2 results
Search Results
Article Citation - WoS: 7Citation - Scopus: 8Internalized Heterosexism and Exposed Psychological Intimate Partner Violence: Experiences of Lesbian and Bisexual Women in Turkey and Denmark(Springer Publishing Co, 2023-04-01) Aracı-İyiaydın, Ayşegül; Toplu-Demirtaş, Ezgi; Ummak, Esra; Toplu-Demirta, EzgiThe current study investigates how associations between internalized heterosexism (IH) and psychological intimate partner violence (IPV) victimization differ for lesbian vs. bisexual (LB) women in Denmark, where queer people are relatively well accepted, and Turkey, where discrimination is still very high. The first purpose of the current study is to explore differences in the prevalence of psychological IPV victimization as a function of sexual orientation (LB women) and country (Denmark and Turkey). As the second purpose, we look at the moderating role of sexual orientation and moderated moderating role of country on the association between IH and psychological IPV victimization. A sample of 257 LB women aged 18-71 years (M = 33.23, SD = 11.15) from Denmark and 152 LB women aged 18-52 years (M = 28.88, SD = 7.70) from Turkey participa- ted. The results of chi-square analyses indicate that LB women from Turkey reported significantly higher psychological IPV victimization than LB women from Denmark. Lesbian than bisexual women from both countries reported more hostile withdrawal and dominance/intimidation-related psychological IPV victimization. The results of moderated moderation analyses reveal that lesbian women in Turkey and bisexual women in Denmark with higher IH were more likely to report experiencing denigration acts. Mental health professionals working with queer psychological IPV survivors may benefit from understanding that IH is associated with LB women's victimization of psychologi- cal IPV, which might be further associated with mental health challenges.Article Citation - Scopus: 24Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: a Retrospective Study Utilizing Two Large Us Claims Databases(Physicians Postgraduate Press Inc., 2017-12-28) Alley, Stephanie; Nguyen, Charles T.; McCarron, Robert M.; Wang, Zhixiao; Xie, Lin; Başer, OnurObjective: Serotonin syndrome (SS) is an adverse drug reaction occurring among patients receiving serotonergic agents (SAs), and although SAs are commonly prescribed, the epidemiology and economic burden of SS with concomitant SA use have not been comprehensively examined. The objective of this study was to investigate the prevalence, incidence, and economic burden of SS with SA use. Methods: A retrospective cohort study was conducted using Veterans Health Administration (VHA) records (identification period: October 1, 2008-September 30, 2012) and commercially insured patient records (Intercontinental Marketing Services PharMetrics Plus; identification period: January 1, 2010-December 31, 2013). Cohorts were based on drug classification and exposure: single monoamine oxidase inhibitor (MAOI), MAOIs in combination with SAs, single non-MAOI SA, and multiple non-MAOI SAs (2, 3, 4, ? 5). Participants were aged ? 18 years with continuous health plan enrollment for 12 months prior to the first SA claim. Outcomes were SS events (ICD-9-CM: 333.99), annual incidence and prevalence, related health care utilization and costs, and SS incidence relative risk. Results: Over 15 million patients were identified and categorized by SA prescription type. SS incidence in both populations decreased: 0.19%-0.07% (VHA) and 0.17%-0.09% (commercially insured). Overall SS prevalence decreased during the study period. Compared to single non-MAOI SA patients, SS incidence relative risk was highest among patients prescribed ? 5 non-MAOI SAs. Inpatient stays accounted for 4.35% (VHA) and 0.88% (commercially insured) of all SS events. Of SS-related inpatient stays, median costs were $8,765 (VHA) and $10,792 (commercially insured). Conclusions: SS incidence and prevalence and SS-related hospitalization risk among patients prescribed SAs were low in both populations. This study provides additional information regarding SS risk associated with SA use. © 2017, Physicians Postgraduate Press Inc. All rights reserved.